July 2015, Special ASCO Edition

← Back to Issue

Sharing the Best of ASCO

Letter to Our Readers

Dear Colleague,

Each year, we look forward to the American Society of Clinical Oncology (ASCO) Annual Meeting where the oncology community gathers to review the past year and discuss the lessons and successes that will impact the lives of patients. The value in gathering is not only in sharing what we have learned over the past year, but also in renewing our enthusiasm for our chosen profession and enabling us to provide the best in care for our patients.

This year, we are pleased to offer our readers highlights from ASCO in this special edition of Personalized Medicine in Oncology (PMO). It comes as no surprise that the talk of the meeting centered on the progress being made in immunotherapeutic approaches to the treatment of cancers. You will find several feature articles reviewing the topic to include updates in several disease states, biomarkers for immunotherapies, and combination strategies with targeted therapies.

We also turn our attention to a host of other topics, most notably the progress in our understanding of genetics and biomarkers and of lung, prostate, breast, thyroid, kidney, and other cancers. Additionally, the format of this special edition of PMO allows us to expand our focus beyond that of personalized medicine to targeted therapies, biomarkers, and immunotherapies. In this supplement, we explore the topic of value-based care and associated costs. We address this topic in several articles in the hope of providing you a full perspective.

Thank you for your loyal readership. It is our mission to provide you with the most compelling and important information to help you bring the best care to those in need.


Coeditor in Chief
Personalized Medicine in Oncology

Immunotherapy - August 13, 2015

Nivolumab Is Superior to Docetaxel as Second-Line Therapy for Patients with NSCLC

Immunotherapy with the programmed death-1 (PD-1) inhibitor nivolumab as second-line therapy prolonged survival in patients with nonsquamous non–small cell lung cancer (NSCLC) who had experienced disease progression with standard platinum-based therapy. The patients in the nivolumab group lived an average of 3 months longer compared with patients receiving docetaxel in [ Read More ]

Value-Based Cancer Care - August 13, 2015

Cost-Effectiveness of T-DM1 Examined

For the treatment of advanced HER2-positive breast cancer, the use of trastuzumab emtansine (T-DM1) is not cost-effective when compared with lapatinib plus capecitabine from both a societal and a payer’s perspective, according to an analysis conducted at Western University of Health Sciences College of Pharmacy in Pomona, CA. From a [ Read More ]